The country’s largest employer-sponsored health benefits program is the latest to update its policy for weight loss drug coverage amid cost pressures.
Both before and during a member’s treatment with anti-obesity drugs, Federal Employees Health Benefits Program — including the Postal Service Health Benefits Program — carriers will need to see documented participation in evidence-based intensive behavioral therapy. This requirement applies for 2027, a document from the U.S. Office of Personnel Management said.
According to Baltimore-based Johns Hopkins Medicine, IBT is an obesity treatment that addresses related health habits. Plans will need to cover specified individual and group IBT and medical nutrition therapy services. Based on a member’s progress, this includes 12 to 22 IBT sessions annually. Plans will still cover a minimum of one GLP-1 anti-obesity medication and two oral anti-obesity medications.
OPM said the overall average premium increases for 2027 were 9.3% and 6.7% for FEHB and PSHB, respectively. The average enrollee share increases are 10.9% for FEHB and 8.2% for PSHB. OPM partially attributed premium increases to higher prescription drug spending, particularly on GLP-1s.
Recently, employers have struggled to navigate GLP-1 coverage for weight loss. Deloitte and Philadelphia-based Jefferson Health, for example, have resorted to lifestyle programs as they grapple with costs.
The federal benefits open season runs from Nov. 9 through Dec. 14.
